Organovo Holdings, Inc. Stock price

Equities

ONVO

US68620A2033

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
1.03 USD +1.98% Intraday chart for Organovo Holdings, Inc. 0.00% -7.21%
Sales 2022 1.5M Sales 2023 370K Capitalization 19.08M
Net income 2022 -11M Net income 2023 -17M EV / Sales 2022 4.16 x
Net cash position 2022 26.49M Net cash position 2023 14.2M EV / Sales 2023 13.2 x
P/E ratio 2022
-2.86 x
P/E ratio 2023
-1.11 x
Employees 18
Yield 2022 *
-
Yield 2023
-
Free-Float 96.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.97%
1 week+1.84%
Current month+2.84%
1 month+3.86%
3 months-7.17%
6 months-17.40%
Current year-5.50%
More quotes
1 week
0.99
Extreme 0.99
1.20
1 month
0.98
Extreme 0.981
1.24
Current year
0.89
Extreme 0.8911
1.27
1 year
0.89
Extreme 0.8911
2.31
3 years
0.89
Extreme 0.8911
11.25
5 years
0.89
Extreme 0.8911
23.92
10 years
0.89
Extreme 0.8911
185.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 06-12-31
Director of Finance/CFO 60 21-09-30
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 60 12-01-31
Chief Executive Officer 52 06-12-31
Director/Board Member 71 20-09-14
More insiders
Date Price Change Volume
24-03-28 1.03 +1.98% 43 804
24-03-27 1.01 -3.81% 65,959
24-03-26 1.05 +1.94% 160,498
24-03-25 1.03 +0.98% 858,445
24-03-22 1.02 -0.97% 65,597

Delayed Quote Nasdaq, March 28, 2024 at 12:06 pm EDT

More quotes
Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.
More about the company
  1. Stock
  2. Equities
  3. Stock Organovo Holdings, Inc. - Nasdaq